Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone

AIMS/INTRODUCTION: Sodium–glucose cotransporter 2 inhibitors, as well as thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative studies have been reported. Dapagliflozin has shown non‐inferiority compared with pioglitazone for glycemic control, and superiority reg...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Diabetes Investig
Main Authors: Cho, Kyu Yong, Nakamura, Akinobu, Omori, Kazuno, Takase, Takahiro, Miya, Aika, Yamamoto, Kohei, Nomoto, Hiroshi, Kameda, Hiraku, Taneda, Shinji, Kurihara, Yoshio, Aoki, Shin, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8264405/
https://ncbi.nlm.nih.gov/pubmed/33131199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.13457
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados